AU2003256059A1 - Non-psychotropic cannabinoids for prevention of cognitive impairment - Google Patents

Non-psychotropic cannabinoids for prevention of cognitive impairment Download PDF

Info

Publication number
AU2003256059A1
AU2003256059A1 AU2003256059A AU2003256059A AU2003256059A1 AU 2003256059 A1 AU2003256059 A1 AU 2003256059A1 AU 2003256059 A AU2003256059 A AU 2003256059A AU 2003256059 A AU2003256059 A AU 2003256059A AU 2003256059 A1 AU2003256059 A1 AU 2003256059A1
Authority
AU
Australia
Prior art keywords
saturated
unsaturated
cyclic
branched
linear
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003256059A
Other languages
English (en)
Inventor
George Fink
Aaron Garzon
Seth Kindler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmos Corp
Original Assignee
Pharmos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IL2003/000604 external-priority patent/WO2004023340A2/en
Application filed by Pharmos Corp filed Critical Pharmos Corp
Publication of AU2003256059A1 publication Critical patent/AU2003256059A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2003256059A 2002-09-05 2003-09-04 Non-psychotropic cannabinoids for prevention of cognitive impairment Abandoned AU2003256059A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40895802P 2002-09-05 2002-09-05
US60/408,958 2002-09-05
AU2003245023 2003-07-23
PCT/IL2003/000604 WO2004023340A2 (en) 2002-09-05 2003-07-23 Non-psychotropic cannabinoids for prevention of cognitive impairment
PCT/IL2003/000735 WO2004021974A2 (en) 2002-09-05 2003-09-04 Non-psychotropic cannabinoids for prevention of cognitive impairment

Publications (1)

Publication Number Publication Date
AU2003256059A1 true AU2003256059A1 (en) 2004-03-29

Family

ID=31980345

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003256059A Abandoned AU2003256059A1 (en) 2002-09-05 2003-09-04 Non-psychotropic cannabinoids for prevention of cognitive impairment

Country Status (3)

Country Link
JP (1) JP2006502159A (https=)
AU (1) AU2003256059A1 (https=)
WO (1) WO2004021974A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
CA3204546A1 (en) * 2021-01-15 2022-07-21 Cambridge Cognition Limited Methods and systems of identifying individuals for perioperative neurocognitive disorder and/or post-viral cognitive impairment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521215A (en) * 1989-11-07 1996-05-28 Ramot University Authority For Applied Research And Industrial Development Ltd. NMDA-blocking pharmaceuticals
US5284867A (en) * 1989-11-07 1994-02-08 Yissum Research Development Company Of The Hebrew University In Jerusalem NMDA-blocking pharmaceutical compositions
US6096740A (en) * 1990-11-06 2000-08-01 Ramot University Authority For Applied Research And Industrial Development Ltd. Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions
US6211230B1 (en) * 1999-09-27 2001-04-03 The United States Of America As Represented By The Secretary Of The Army Method of reducing brain damage resulting from seizures

Also Published As

Publication number Publication date
WO2004021974A2 (en) 2004-03-18
JP2006502159A (ja) 2006-01-19
WO2004021974A3 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
KR102073578B1 (ko) App 특이적 bace 억제제(asbi) 및 이의 용도
AU2017413260B2 (en) Composition comprising uric acid for the treatment of brain stroke patients treated with mechanical thrombectomy
JP5314931B2 (ja) 加齢黄斑変性の予防又は治療剤
JP2010511701A (ja) 水素化ピリド（４，３−ｂ）インドール（異性体）に基づいた、発作を含む脳循環の急性および慢性疾患の治療のための手段、それに基づいた薬理学的手段、およびその使用のための方法
JP2002522483A (ja) 視覚障害および記憶障害のための複素環式チオエステルのｎ−結合スルホンアミド
US20090076105A1 (en) Preventive or therapeutic agent for cerebral ischemic injury or cerebral ischemia reperfusion in stroke
RU2336870C2 (ru) Применение l-бутилфталида для изготовления лекарственного средства для профилактики и лечения церебрального инфаркта
RU2426535C2 (ru) Применение бета-гидроксибутирата или его фармацевтически приемлемых солей для приготовления лекарственного средства, обладающего цитопротекторной активностью, включающей нейропротекторную, кардиопротекторную, противоишемическую, антигипоксическую, антистрессорную, актопротекторную и адаптогенную активности, лекарственное средство и способ профилактики, купирования и лечения с помощью этого лекарственного средства
JPH02180820A (ja) アセチル―ｌ―カルニチン白内障処置剤
Yin et al. Angiopoietin-1 protects spinal cord ischemia and reperfusion injury by inhibiting autophagy in rats
JP2002522479A (ja) 視覚障害および記憶障害のためのｎ−複素環式カルボン酸またはそのイソスターのｎ−結合スルホンアミド
EP0887078A1 (en) Use of L or DL-threo-DOPS for preventing and treating the consequences of cerebral ischemia
CN108348524A (zh) 用于从中风恢复的方法和组合物
AU2003256059A1 (en) Non-psychotropic cannabinoids for prevention of cognitive impairment
US20050192341A1 (en) Non-psychotropic cannabinoids for prevention of cognitive impairment
JP2011144111A (ja) 軸性近視の予防または治療剤
JP6271539B2 (ja) バクロフェン及びアカンプロセートに基づいた黄斑変性疾患の治療法
CA2497164A1 (en) Non-psychotropic cannabinoids for prevention of cognitive impairment
CN1403088A (zh) 含虎杖甙或其盐的药用组合物及其在药物制备中的用途
EP2184284B1 (en) Preventive, inhibitor or remedy for cerebral aneurysm comprising ibudilast as an active ingredient
RU2481124C1 (ru) Фармацевтическая комбинация из аторвастатина и ницерголина для профилактики или лечения нарушений мозгового кровообращения
RU2506950C2 (ru) Комбинация карбостирила и карнитина
LU505115B1 (en) Medical use of pf429242 for protecting cerebral ischemia-reperfusion injury
JP2004331502A (ja) 視神経細胞保護剤
JP2009235069A (ja) ３’，５−ジ−２−プロペニル−（１，１’−ビフェニル）−２，４’−ジオールを有効成分として含有する視神経障害の予防又は治療剤

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application